Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Ben, Tran; Horvath, L.; Rettig, M.; Fizazi, K.; Lolkema, M. P.; Dorff, T. B.; Greil, R.; Machiels, J. P. H.; Autio, K. A.; Rottey, S.; Adra, N.; Garje, R.; Roncolato, F.; Tagawa, S. T.; Shariat, S. F.; Salvati, M.; Poon, S.; Kouros-Mehr, H. |
| Abstract Title: | Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368309164 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.TPS5590 |
| Notes: | Meeting Abstract: TPS5590 -- Source: Wos |
